The American Society of Clinical Oncology has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.
If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.
The American Society of Clinical Oncology was awarded $11 million in research funding by the Patient-Centered Outcomes Research Institute to study dosing strategies of oral CDK4/6 inhibitors in older adults living with metastatic breast cancer.
The American Society of Clinical Oncology has published guidelines outlining the need to assess and manage vulnerabilities in patients aged 65 and older prior to prescribing chemotherapy, targeted therapy and/or immunotherapy.
I have no doubt that our professional associations in cancer research and oncology and our NCI in the U.S. care about the plight of cancer scientists and oncologists who have been displaced due to war or violence in their home countries.
Radiation oncologist William Blackstock died from his long battle with prostate cancer June 18. He was 60.
Conquer Cancer, the ASCO Foundation, presented more than $11 million in funding through more than 400 grants and awards spanning multiple areas of cancer care, including precision medicine, palliative care, and breast cancer.
The American Society of Clinical Oncology has issued new clinical guidance for best treating patients with gastrointestinal cancer amidst a nationwide shortage of carboplatin and cisplatin.
The shortage of platinum-based drugs in the United States is an endemic problem—i.e., Europe is unaffected—caused by the absence of transparency, dearth of early warnings, and a lack of redundancy in the supply chain.
Leukemia was mostly a fatal disease when Hagop Kantarjian, a medical student at the American University of Lebanon in Beirut, first came to MD Anderson in 1978.